

# Drug-Resistant Polymorphisms and Copy Numbers in *Plasmodium falciparum*, Mozambique, 2015

Himanshu Gupta, Eusebio Macete, Helder Bulo, Crizolgo Salvador, Marian Warsame, Eva Carvalho, Didier Ménard, Pascal Ringwald, Quique Bassat, Sonia Enosse,<sup>1</sup> Alfredo Mayor<sup>1</sup>

One of the fundamental steps toward malaria control is the use of antimalarial drugs. The success of antimalarial treatment can be affected by the presence of drug-resistant populations of *Plasmodium falciparum*. To assess resistance, we used molecular methods to examine 351 *P. falciparum* isolates collected from 4 sentinel sites in Mozambique for *K13*, *pfmdr1*, *pfcr1*, and *pfdhps* polymorphisms and for *plasmepsin2* (*pfpm2*) and *pfmdr1* copy numbers. We found multiple copies of *pfpm2* in 1.1% of isolates. All isolates carried *K13* wild-type alleles (3D7-like), except 4 novel polymorphisms (Leu619Leu, Phe656Ile, Val666Val, Gly690Gly). Prevalence of isolates with *pfcr1* mutant (K76T) allele was low (2.3%). Prevalence of isolates with *pfdhps* mutant alleles (A437G and K540E) was >80%, indicating persistence of sulfadoxine/pyrimethamine resistance; however, markers of artemisinin were absent, and markers of piperazine resistance were low. Piperazine resistance isolates may spread in Mozambique as dihydroartemisinin/piperazine drug pressure increases.

During the past decade, malaria control strategies have substantially reduced the malaria burden worldwide; several countries are advancing toward malaria elimination (1,2). A fundamental pillar for contributing to the reduction of the malaria burden has been artemisinin-based combination therapy. Unfortunately, the effectiveness of

antimalarial drugs used for malaria treatment and chemoprevention during pregnancy has been threatened by the emergence of drug-resistant parasite populations (2–5).

The emergence of artemisinin resistance in *Plasmodium falciparum*, with reduced in vivo susceptibility to artesunate, was reported in Southeast Asia (3,6). Detectable polymorphisms in the *Kelch 13* (*K13*) propeller domain in *P. falciparum* associated with artemisinin resistance have subsequently provided an additional tool for monitoring resistance to antimalarial drugs (7,8). In Cambodia, polymorphisms in the *K13* propeller domain (mainly Y493H, R539T, I543T, and C580Y) were associated with in vitro prolonged parasite survival rates and in vivo delayed parasite clearance rates (8,9). Recently, *plasmepsin 2* (*pfpm2*) copy number and *pfcr1* C101F polymorphism have been associated with piperazine resistance (10–12). In addition, increased *pfmdr1* copies have been associated with resistance to mefloquine (in vivo, in vitro, or both) and partially to lumefantrine (13–18). Specific point polymorphisms (at codons 86, 184, 1034, 1042, and 1246) of the *pfmdr1* gene have also been linked to resistance to antimalarial drugs (19,20). In field isolates tested in vitro as well as in laboratory lines, N86Y polymorphism was associated with chloroquine resistance (21). Further, polymorphisms in the *pfcr1* gene have also been shown to affect parasite susceptibility to chloroquine (22), amodiaquine (23,24), and artemether/lumefantrine (25). Recently, a nonsynonymous polymorphism in the *pfcr1* gene was shown to be prevalent in the genetic background of *K13* mutant artemisinin-resistant isolates (26). In addition, polymorphisms in *pfdhfr* and *pfdhps* genes, specifically the quintuple mutant, including the *pfdhfr* substitutions N51I, C59R, and S108N, as well as the *pfdhps* substitutions A437G and K540E, have been associated with a failure of sulfadoxine/pyrimethamine treatment against uncomplicated *P. falciparum* malaria (27). In Africa, the *pfdhps* K540E polymorphism has been considered a useful epidemiologic marker of the quintuple mutations (28).

Author affiliations: ISGlobal, Barcelona Institute for Global Health, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain (H. Gupta, Q. Bassat, A. Mayor); Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique (E. Macete, H. Bulo, Q. Bassat, A. Mayor); Instituto Nacional de Saúde, Ministério da Saúde, Maputo (C. Salvador, S. Enosse); World Health Organization Global Malaria Programme, Geneva, Switzerland (M. Warsame, P. Ringwald); World Health Organization, Maputo (E. Carvalho); Malaria Molecular 16 Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia (D. Ménard); Institut Pasteur, Paris, France (D. Ménard); ICREA, Barcelona (Q. Bassat); Pediatrics Department, Hospital Sant Joan de Déu (University of Barcelona), Barcelona, Spain (Q. Bassat)

<sup>1</sup>These authors contributed equally to this article.

The development of drug resistance could be influenced by multiple factors such as polymorphism rate, fitness costs, overall parasite load, strength of drug selection, treatment compliance, transmission intensity, host immunity, and erythrocyte disorders (29–31). Naturally acquired immunity plays a major role in the emergence and clearance of artemisinin-resistant parasites (32). Because of increasing concern over the effectiveness of the nationally recommended antimalarial drugs, the Mozambique Ministry of Health has made several changes in antimalarial drug policy. In 2002, chloroquine monotherapy was replaced with sulfadoxine/pyrimethamine/amodiaquine as the first line of treatment against uncomplicated malaria (33); 2 years later, this combination was replaced with artesunate/sulfadoxine/pyrimethamine (33). In 2008, artemether/lumefantrine was introduced to replace artesunate/sulfadoxine/pyrimethamine (34). Molecular markers for antimalarial drug resistance have been considered useful for confirming parasite resistance, a major factor causing treatment failure. To determine whether parasites carrying these polymorphisms or gene amplifications exist in Mozambique, we conducted molecular surveillance targeting *K13*, *pfmdr1*, *pfprt*, and *pfdhps* polymorphisms and *pfpm2* and *pfmdr1* copy numbers in field isolates collected from 4 sentinel sites.

## Materials and Methods


### Study Sites and Population

We performed a descriptive observational study on blood samples collected before artemether/lumefantrine treatment

(on day 0) in 2015 from 352 symptomatic children at 4 sentinel sites in Mozambique (Figure 1): 1) Hospital Rural de Montepuez in Cabo Delgado Province (northern region), 2) Centro de Saúde de Dondo in Sofala Province (central region), 3) Hospital Provincial de Moatize in Tete Province (central region), and 4) Hospital Rural de Chokwe in Gaza Province (southern region). In Mozambique, transmission usually peaks during the rainy season (November–April). Transmission intensity in southern Mozambique is generally low, although areas of high transmission may still occur (35). To determine molecular markers of drug resistance, we analyzed samples collected during a clinical trial conducted in 2015 (registration no. ACTRN12616001680459); the trial aimed to assess the efficacy and safety of artemether/lumefantrine for treatment of uncomplicated *P. falciparum* malaria in children <5 years of age. The National Mozambican Ethical Review Committee (Mozambique) and Hospital Clínic (Barcelona, Spain) ethics review committees approved the study, and signed written informed consent was obtained from all participants' guardian or parent.

### Molecular Procedures

We extracted DNA from half of a 50- $\mu$ L dried blood drop on Whatman 3-mm filter paper by using a QIAamp DNA Mini kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. We used an ABI PRISM 7500 HT Real-Time System (Applied Biosystems, Foster City, CA, USA) to amplify purified parasite DNA templates, following a previously described method (36,37). A standard curve was prepared from an in vitro culture of 3D7 strain containing known numbers of ring-infected erythrocytes.



**Figure 1.** Location of sampling sites and distribution of resistance markers of *Plasmodium falciparum* in Mozambique, 2015.

The standard curve was run in triplicate for each test with 5 serially diluted points. Parasitemia in the clinical samples was quantified by extrapolation against the standard curve.

To assess polymorphisms in the *K13*, *pfprt*, *pfmdr1*, and *pfdhps* genes, we amplified purified DNA templates by using a 2720 Thermal Cycler (Applied Biosystems), following protocols described for *K13* PCR (38) and *pfprt* PCR (35). To genotype polymorphisms in *pfmdr1* and *pfdhps* genes, we designed new assays by using Sanger sequencing and restriction fragment length polymorphisms (online Technical Appendix, <https://wwwnc.cdc.gov/EID/article/24/1/17-0864-Techapp1.pdf>). A total of 6 positive controls with known *K13* alleles, provided by the Institut Pasteur in Cambodia, and 4 parasite lines (3D7, 7G8, Dd2, and V1/S) with known *pfprt* and *pfmdr1* alleles, available in the laboratory, were also processed, amplified, and sequenced at the same time as the studied samples (PCR characteristics in online Technical Appendix Table). To determine the detection limit of Sanger sequencing, we used artificially mixed DNA samples of *P. falciparum* laboratory strains containing various known proportions of wild- and mutant-type alleles of *pfprt* (K76T) and *pfmdr1* (Y184F and S1034C) genes. To estimate polymorphism frequency, we considered isolates with mixed alleles to be mutated.

We assessed copy numbers of *pfpm2* and *pfmdr1* genes as described elsewhere (11) with minor changes (online Technical Appendix) by using quantitative PCR (qPCR). We performed amplification in 20- $\mu$ L reaction mixtures for *pfpm2*, *pfmdr1*, and *pf $\beta$ -tubulin* genes, separately. We used the *pf $\beta$ -tubulin* gene as an endogenous control. All samples with estimated copy numbers >1.5 were defined as containing multiple copies and repeated for confirmation. The estimated copy numbers were the average of the copy number of each clone in the isolate.

### Data Analyses

We calculated the proportion of the mutant alleles and isolates with multiple copies of *pfpm2* and *pfmdr1* genes on the basis of the number of samples with wild- and mutant-type alleles as well as isolates with single and multiple copies of the gene from *P. falciparum* isolates from each study site. To compare continuous data and categorical data between sites, respectively, we performed analyses of variance and  $\chi^2$  tests. We defined statistical significance as  $p < 0.05$ .

## Results

### Demographics and *P. falciparum* Infection

Among the 352 blood samples collected before artemether/lumefantrine treatment (on day 0) during 2015, and followed up as part of the clinical trial, 351 (99.7%) were *P. falciparum*-infection positive according to 18SrRNA qPCR. The mean ( $\pm$  SD) parasitemia (by qPCR) was  $100,229 \pm 325,214$  parasites/ $\mu$ L. Among participants, 159 (45.2%) were female, mean ( $\pm$  SD) age was  $2.8 \pm 1.3$  y, mean body temperature was  $38.1 \pm 1.1^\circ\text{C}$ , and mean hemoglobin level was  $9.2 \pm 1.9$  g/dL. We also compared demographic data and parasite densities according to study site (Table 1). Efficacy of artemether/lumefantrine in the in vivo study was high, and for nearly all patients (349 [99.4%] of 351), parasitemia reverted to 0 in the first 3 days; however, for 2 patients, parasites were still detectable by microscopy: 1 from Moatize (514 parasites/ $\mu$ L) and 1 from Chokwe (3,763 parasites/ $\mu$ L). PCRs targeting *msp1*, *msp2*, and *glurp* genes were used to differentiate recrudescence (same parasite strain) and reinfection (different parasite strain). We noted recrudescence of *P. falciparum* infections for 5 children (1 in Chokwe, 3 in Moatize, and 1 in Montepuez) on days 21 and 28 after artemether/lumefantrine administration and reinfection for 7 children (3 in Moatize and 4 in Montepuez); 3 were reinfected on day 21 and 4 on day 28 (39).

The polymorphism analyses of *K13*, *pfmdr1*, *pfprt*, and *pfdhps* genes were successful for 98.3% to 100% isolates. Because no amplifications were noticed in negative controls (with water and human genomic DNA), PCR assays were specific to *P. falciparum* genomic DNA only.

### Detection Limit of Mixed Samples by Sanger Sequencing

We identified "A" alleles of *pfprt* (K76T) and *pfmdr1* (Y184F) codons in artificially mixed samples by using Sanger sequencing when the proportion of target DNA was  $\geq 10\%$ . However, we identified "C" and "T" alleles of *pfprt* (K76T) and *pfmdr1* (Y184F) polymorphisms, respectively, in mixed samples when their proportion was  $\geq 20\%$  (online Technical Appendix Figure 1). For *pfmdr1* (S1034C) polymorphism, the minor allele was detected when its proportion was  $\geq 20\%$  in a mixed sample (online Technical

**Table 1.** Characteristics of study participants with *Plasmodium falciparum* malaria, by site, Mozambique, 2015

Characteristic	Montepuez, n = 87	Dondo, n = 88	Moatize, n = 89	Chokwe, n = 88	p value
Female, no. (%)	36 (41.4)	40 (45.5)	41 (46.1)	42 (47.7)	0.63
Age, y, mean $\pm$ SD	$2.4 \pm 1.1$	$2.7 \pm 1.1$	$2.7 \pm 1.1$	$3.1 \pm 1.1$	0.0002
Temperature, $^\circ\text{C}$ , mean $\pm$ SD	$37.9 \pm 0.9$	$38.5 \pm 1.1$	$38.1 \pm 1.0$	$37.9 \pm 1.5$	0.0043
Parasite density, parasites/ $\mu$ L, mean $\pm$ SD*	$1.2 \times 10^5 \pm 1.3 \times 10^5$	$3.7 \times 10^4 \pm 4.4 \times 10^4$	$1.2 \times 10^5 \pm 6.1 \times 10^5$	$1.2 \times 10^5 \pm 1.8 \times 10^5$	<0.0001
Hemoglobin, g/dL, mean $\pm$ SD	$8.9 \pm 2.2$	$8.7 \pm 1.8$	$9.8 \pm 1.7$	$9.2 \pm 2.0$	0.0018

\*By quantitative PCR.

Appendix Figure 1, panel C). For positive controls, we used several parasite lines with known *K13*, *pfmdr1*, and *pfcr1* alleles. As expected, sequencing analysis of all positive controls revealed wild- and mutant-type alleles of *K13*, *pfmdr1*, and *pfcr1* polymorphisms.

### Copy Numbers for *pfpm2* and *pfmdr1*

We successfully analyzed 351 (100%) samples for copy number variation in the *pfpm2* and *pfmdr1* genes. PCR efficiencies were 98.4% for *pfpm2*, 97.2% for *pfmdr1*, and 99.2% for *pfβ-tubulin* genes. As expected, the estimated *pfpm2* and *pfmdr1* copy numbers for the positive controls were 3–4 copies. The estimated mean (interquartile range) copy numbers were 3.51 (3.37–3.62) for *pfpm2* and 3.62 (3.51–3.79) for *pfmdr1* positive controls. When we used a copy number threshold of 1.5 to define multiple copies, only 4 (1.1%) and 5 (1.4%) of the 351 isolates had multiple copies of *pfpm2* and *pfmdr1*, respectively (Table 2; Figure 2). The range of estimated *pfpm2* copy numbers was 0.59–1.79 and of *pfmdr1* was 0.58–1.88. The copy number of *pfpm2* and *pfmdr1* genes did not significantly differ between isolates from different sites. The proportion of isolates with multiple copies of the *pfpm2* gene was the highest at Chokwe (2 [2.3%] of 87). Only 1 (1.1%) of 88 samples from Dondo had multiple copies of *pfpm2* and *pfmdr1* genes.

### *K13* Polymorphisms

We successfully achieved *K13* PCR and sequencing for all 351 isolates. None of the isolates analyzed contained the polymorphisms most frequently found in isolates from Cambodia (8). However, we observed 4 novel polymorphisms at nt 1725147 (codon 619; 0.28% [1/351]); 1725032 (codon 656; 0.28% [1/351]); 1725000 (codon 666; 0.57% [2/351]); and 1724927 (codon 690; 0.85% [3/351]) of the *K13* gene. All polymorphisms were synonymous except for 1 at codon 656, which led to a change from phenylalanine to isoleucine. When we compared frequencies of new polymorphisms between sites, we found no significant differences. We also observed the polymorphism Cys469Cys, previously described in *P. falciparum* field isolates from Ghana (40), in 3 (0.85%) of the 351 isolates. Isolates from patients with parasitemia on day 3 and recrudescence contained wild-type *K13* gene polymorphisms.

### *pfcr1* Polymorphisms

We successfully amplified all 351 samples for *pfcr1* and sequenced the amplification products; mutant alleles were found at codons M74I, N75E, and K76T only in 8 (2.3%) samples. The mutant alleles (M74I, N75E, and K76T) were present only in isolates collected from Chokwe (8 [9.2%] of 87). When we compared frequencies of mutant alleles between sites, the difference was significant ( $p < 0.0001$ ). In the studied isolates, the mutant (F) allele at codon 101 was absent. Isolates from patients with parasitemia on day 3 and recrudescence contained wild-type *pfcr1* gene polymorphisms.

### *pfmdr1* Polymorphisms

We successfully amplified and sequenced *pfmdr1\_f1* for 351 (100%) samples and *pfmdr1\_f2* fragments for 350 (99.7%) samples. We identified 15 polymorphisms all across the *pfmdr1* gene, including 5 (33.3%) with nonsynonymous polymorphisms and 10 (66.7%) with synonymous polymorphisms. Among nonsynonymous polymorphisms, 3 (T1192A, F1194S, and Y1197N) were newly identified and 2 (N86Y and Y184F) had been previously reported (41). Among synonymous polymorphisms, 7 (L1030L, D1061D, D1127D, S1137S, L1174L, D1179D, and N1189N) were newly identified and 3 (G102G, G182G, and T1069T) had been previously reported (41). Among the 351 isolates, we found 11 (3.1%) N86Y and 164 (46.7%) Y184F mutant alleles (Table 3). All newly identified nonsynonymous mutant alleles were present only once, except for Y1197N, which was found twice (0.6% [2/350]). The frequency of polymorphisms (N86Y and D1179D) differed significantly between isolates from the 4 sites (Table 3). The proportion of N86Y and D1179D polymorphisms was highest in isolates from Chokwe. We observed none of the other most frequent polymorphisms (S1034C, N1042D, and D1246Y) of the *pfmdr1* gene among the analyzed samples. Isolates from patients with parasitemia on day 3 and recrudescence contained wild-type *pfmdr1* gene polymorphisms.


### *pfdhps* Polymorphisms

Polymorphism analysis by PCR followed by sequencing for S436F and A437G polymorphisms was successful for 345 (98.3%) samples and analysis by PCR–restricted fragment length polymorphism for K540E polymorphism for 348 (99.1%) samples. Among all isolates, 10 (2.9%) of 345

**Table 2.** *Plasmodium falciparum* isolates with increased *pfpm2* and *pfmdr1* gene copy numbers, 4 sentinel sites, Mozambique, 2015

Site	<i>pfpm2</i>				<i>pfmdr1</i>			
	No. (%)			Mean ± SD	No. (%)			Mean ± SD
	≤1.2	1.2–1.5	≥1.5		≤1.2	1.2–1.5	≥1.5	
Montepueuz, n = 87	82 (94.3)	5 (5.7)	0	0.85 ± 0.2	87 (100.0)	0	0	0.93 ± 0.1
Dondo, n = 88	66 (75.0)	21 (23.9)	1 (1.1)	1.02 ± 0.2	68 (77.3)	18 (20.4)	2 (2.3)	0.99 ± 0.3
Moatize, n = 89	73 (82.0)	15 (16.9)	1 (1.1)	1.01 ± 0.2	81 (91.0)	7 (7.9)	1 (1.1)	0.99 ± 0.2
Chokwe, n = 87	77 (88.5)	8 (9.2)	2 (2.3)	0.94 ± 0.2	70 (80.5)	15 (17.2)	2 (2.3)	0.98 ± 0.2





**Figure 2.** *pfpm2* and *pfmdr1* copy numbers of *Plasmodium falciparum* isolates from 4 sentinel sites, Mozambique, 2015. Multiple copies of *pfpm2* and *pfmdr1* genes have been associated with resistance to piperazine and mefloquine, respectively.

contained S436F, 289 (83.8%) of 345 contained A437G, and 286 (82.2%) of 348 contained K540E mutant alleles. At codon 436, we also found 3 mutant alleles: S436C (0.9%), S436A (4.9%), and S436H (0.6%). When we compared frequencies of 3 single-nucleotide polymorphisms at different sites, we noted significant differences (Table 4). The proportion of isolates with A437G and K540E polymorphisms was the highest at Moatize, and the proportion with S436F, S436C, S436A, and S436H alleles was highest at Montepuez.

## Discussion

We provide evidence for the presence of multiple copies of *pfpm2* in 4 (1.1%) of 351 *P. falciparum* isolates circulating in southern Mozambique despite the absence of piperazine drug pressure. Thus, with adequate drug pressure, isolates resistant to piperazine may spread in Mozambique, as occurred in Southeast Asia (10,42,43). In selected areas of Cambodia in 2008, piperazine was introduced as a partner drug of artemisinin (44). Soon after its introduction, as early as 2010, piperazine resistance in western Cambodia emerged at an alarming rate (45). Subsequent reports confirmed a rapid increase in failure of dihydroartemisinin/piperazine in other parts of Cambodia (42,46,47). The most frequent *K13* mutants associated with artemisinin resistance were absent in the isolates from Mozambique. We also determined that prevalence of *pfprt* (K76T) and *pfmdr1* (N86Y) markers

of resistance are low, supporting previous evidence for the return of parasites carrying *pfprt* wild-type alleles in Mozambique (35), in contrast to persistence of *pfdhps* (A437G [83.8%]) and K540E [82.2%]) polymorphisms, markers of sulfadoxine/pyrimethamine resistance (34). The well-characterized polymorphism in *pfmdr1* (Y184F [46.7%]) was also prevalent in Mozambique.

We found very low prevalence (<1%) for 4 new polymorphisms (Leu619Leu, Phe656Ile, Val666Val, and Gly690Gly) in the *K13* gene of *P. falciparum* isolates from Mozambique. All polymorphisms except Phe656Ile were synonymous. Previously, V494I *K13* nonsynonymous polymorphism has also been reported in Mozambique (48). In Africa, *K13* nonsynonymous polymorphisms have also been reported at low frequencies in isolates from Cameroon, Central African Republic, Democratic Republic of the Congo, Gabon, The Gambia, Kenya, Madagascar, Malawi, Mali, Rwanda, Togo, Uganda, Zambia, and Equatorial Guinea (38,40,49–50; references 51,52 in online Technical Appendix). The association of nonsynonymous polymorphisms with delayed parasite clearance has only recently been identified in Africa (reference 52 in online Technical Appendix).

Resistance to both chloroquine and amodiaquine has been mainly associated with a single K76T mutant allele in the *pfprt* gene (22–24). In our study, its prevalence in 8 (2.3%) of 351 samples was significantly lower than that found in previous studies in Mozambique (33,34;

**Table 3.** Distribution of *Plasmodium falciparum* *pfmdr1* polymorphism (mutated allele) frequencies among 4 sentinel sites, Mozambique, 2015\*

SNP	Montepuez, no. (%)	Chokwe, no. (%)	Moatize, no. (%)	Dondo, no. (%)	p value
N86Y	1 (1.1)	6 (6.9)	0	4 (4.5)	0.03
G102G	1 (1.1)	2 (2.3)	2 (2.2)	1 (1.1)	0.88
G182G	4 (4.6)	1 (1.1)	3 (3.4)	1 (1.1)	0.37
Y184F	45 (51.7)	39 (44.8)	42 (47.2)	38 (43.2)	0.69
L1030L	0	0	1 (1.1)	0	0.40
D1061D	0	1 (1.1)	0	0	0.40
T1069T	10 (11.5)	5 (5.7)	4 (4.5)	8 (9.2)	0.28
D1127D	1 (1.1)	0	2 (2.2)	0	0.30
S1137S	2 (2.3)	0	0	2 (2.3)	0.25
L1174L	1 (1.1)	0	0	0	0.40
D1179D	0	9 (10.3)	2 (2.2)	0	0.0001
N1189N	0	0	1 (1.1)	1 (1.1)	0.57
T1192A	0	1 (1.1)	0	0	0.40
F1194S	1 (1.1)	0	0	0	0.40
Y1197N	1 (1.1)	0	0	1 (1.1)	0.57

\*SNP, single-nucleotide polymorphism.

reference 53 in online Technical Appendix). Our *pfert* data align with previous evidence for the return of parasites carrying *pfert* wild-type alleles in Mozambique (35) and in other countries in Africa, such as Ethiopia (reference 54 in online Technical Appendix), Malawi (reference 55 in online Technical Appendix), and Cameroon (reference 56 in online Technical Appendix). The selective disadvantage of mutant parasites in the absence of drug pressure has been proposed as the leading factor contributing to the reemergence of chloroquine-susceptible parasites (reference 57 in online Technical Appendix). Because artemether/lumefantrine has been shown to select for the wild-type *pfert* 76K allele (25), this reemergence might be accelerated because of the increased use of artemether/lumefantrine as a first-line treatment for uncomplicated malaria in Mozambique (reference 53 in online Technical Appendix).

Our study also provides evidence for the presence of few *P. falciparum* isolates with multiple copies of the *pfmdr1* gene (5 [1.4%] of 351) circulating in southern Mozambique (34). Increased *pfmdr1* copies have been associated with resistance to mefloquine and partial resistance to lumefantrine (13–18). Our study found that prevalence of the *pfmdr1* N86Y mutant allele has decreased and the Y184F mutant allele has increased over time, in contrast with findings of other studies from Mozambique (34; references 55,58 in online Technical Appendix). We identified 10 new polymorphisms (L1030L, D1061D, D1127D, S1137S, L1174L, D1179D, N1189N, T1192A, F1194S, and Y1197N) that had not been previously described for the *pfmdr1* gene. Among the 15

polymorphisms identified in the *pfmdr1* gene, we observed significant differences between sites for the N86Y and D1179D polymorphisms only.

Of 351 children who had received adequate treatment with artemether/lumefantrine (6 doses), 2 were still positive for parasitemia on day 3 (39). These isolates contained wild-type *K13* gene polymorphisms. *P. falciparum*-positive patients for whom artemether/lumefantrine treatment failed had parasites that carried wild-type *pfert* and *pfmdr1* polymorphisms. This observation suggests that in vivo artemether/lumefantrine resistance may be caused not only by variations in the *pfert* and *pfmdr1* genes but possibly by parasite selection of variations in other genes; however, drug bioavailability issues may also have contributed.

A high proportion of the *P. falciparum* isolates from Mozambique contained K540E (82.2%) and A437G (83.8%) mutant alleles. These mutant alleles may still not jeopardize the effectiveness of sulfadoxine/pyrimethamine for malaria prevention in Mozambique; recent findings suggest that only >90% prevalence of a *pfdhps* K540E polymorphism could reduce the effectiveness of intermittent preventive therapy to clear peripheral parasites and prevent new infections during pregnancy (reference 59 in online Technical Appendix). Therefore, sulfadoxine/pyrimethamine remains effective for intermittent preventive therapy during pregnancy, despite the high frequency of quintuple mutants; thus, the World Health Organization continues to recommend the use of intermittent preventive therapy to prevent malaria during pregnancy (references 60–62 in online Technical Appendix).

**Table 4.** Distribution of *Plasmodium falciparum* *pfdhps* gene polymorphism (mutated allele) frequencies among 4 sentinel sites, Mozambique, 2015\*

SNP	Montepuez, no. (%)	Chokwe, no. (%)	Moatize, no. (%)	Dondo, no. (%)	p value
S436F/C/A/H	30 (34.5)	2 (2.4)	0	0	<0.0001
A437G	51 (58.6)	79 (94.1)	82 (93.2)	77 (89.5)	<0.0001
K540E	50 (57.5)	77 (90.6)	83 (93.3)	76 (87.4)	<0.0001
A437G + K540E	47 (54.1)	77 (91.7)	80 (90.9)	76 (88.4)	<0.0001

\*SNP, single-nucleotide polymorphism.

However, alternative antimalarial drugs for intermittent preventive therapy during pregnancy are needed because the prevalence of the K540E polymorphism in Mozambique is close to the threshold.

In conclusion, we report that prevalence of isolates with multiple copies of *pfpm2* is lower than that found by previous studies in Cambodia (34.3%) and Vietnam (54.3%) (10,43), and we report the absence of *K13* polymorphisms known to be associated with artemisinin resistance. We also report the return of parasites carrying *pfcr* wild-type alleles (except in Chokwe) and persistence of parasites with *pfdhps* mutations associated with sulfadoxine/pyrimethamine resistance in Mozambique. Sulfadoxine/pyrimethamine-resistant isolates may be maintained by the constant use of intermittent preventive therapy during pregnancy, use of drug outside of hospitals, the very common use of co-trimoxazole (as prophylaxis for HIV-infected persons), and the low fitness cost of the polymorphisms (33; references 63,64 in online Technical Appendix). In contrast, the fitness cost of the *pfcr* mutant allele seems to be high, probably accounting for the return of parasites carrying *pfcr* wild-type alleles in Mozambique (reference 57 in online Technical Appendix). Current regional elimination efforts, as part of the G8 Malaria Elimination Initiative, may lead to more aggressive strategies involving population-wide distribution of antimalarial drugs, such as dihydroartemisinin/piperazine, resulting in significantly increased drug pressure. Our findings might provide baseline prevalence data that enable us to directly determine the effects that increasing malaria control efforts or elimination programs will have on resistance evolution.

### Acknowledgments

We thank all study participants, field workers, laboratory workers, and everyone who supported this study directly or indirectly. We also thank Silvie Huijben, Mercedes Rubio, and Nilo Ortiz de Zugasti Carrón for their useful comments on this manuscript.

We thank the World Health Organization for providing the funds for this study, as well as the Instituto de Salud Carlos III (PI13/01478 cofunded by the Fondo Europeo de Desarrollo Regional, and CES10/021-I3SNS) to A.M. A.M. is also supported by the Departament d'Universitats i Recerca de la Generalitat de Catalunya, Agència de Gestió d'Ajuts Universitaris i de Recerca (2014SGR263). H.G. has a fellowship from the Overseas Postdoctoral Fellowship program by the Science and Engineering Research Board, Department of Science & Technology, Government of India (SB/OS/PDF-043/2015-16). The Centro de Investigação em Saude de Manhica receives major core funding from the Spanish Agency for International Cooperation. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya.

M.W. and P.R. are staff members of the World Health Organization. These authors alone are responsible for the views expressed in this publication, and they do not necessarily represent the decisions, policy, or views of the World Health Organization.

Dr. Gupta is a postdoctoral fellow at the ISGlobal, Barcelona Centre for International Health Research, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain. His research focus is use of molecular tools for the active surveillance of emerging drug resistance, gene deletions, and afebrile malaria in malaria-endemic regions.

### References

- O'Meara WP, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. *Lancet Infect Dis*. 2010;10:545–55. [http://dx.doi.org/10.1016/S1473-3099\(10\)70096-7](http://dx.doi.org/10.1016/S1473-3099(10)70096-7)
- World Health Organization. World malaria report 2016 [cited 2017 Mar 24]. <http://apps.who.int/iris/bitstream/10665/252038/1/9789241511711-eng.pdf?ua=1>
- Dondorp AM, Nosten F, Yi P, Das D, Phylo AP, Tarning J, et al. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2009;361:455–67. <http://dx.doi.org/10.1056/NEJMoa0808859>
- Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. *Clin Infect Dis*. 2011;53:224–30. <http://dx.doi.org/10.1093/cid/cir376>
- Hamer DH, Ndhlovu M, Zurovac D, Fox M, Yeboah-Antwi K, Chanda P, et al. Improved diagnostic testing and malaria treatment practices in Zambia. *JAMA*. 2007;297:2227–31. <http://dx.doi.org/10.1001/jama.297.20.2227>
- Noedl H, Se Y, Schaefer K, Smith BL, Socheat D, Fukuda MM; Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. Evidence of artemisinin-resistant malaria in western Cambodia. *N Engl J Med*. 2008;359:2619–20. <http://dx.doi.org/10.1056/NEJMc0805011>
- World Health Organization. Artemisinin and artemisinin-based combination therapy resistance. Status report. 2017 [cited 2017 May 5]. <http://apps.who.int/iris/bitstream/10665/255213/1/WHO-HTM-GMP-2017.9-eng.pdf?ua=1>
- Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature*. 2014;505:50–5. <http://dx.doi.org/10.1038/nature12876>
- Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al.; Tracking Resistance to Artemisinin Collaboration (TRAC). Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2014;371:411–23. <http://dx.doi.org/10.1056/NEJMoa1314981>
- Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J et al. A surrogate marker of piperazine-resistant *Plasmodium falciparum* malaria: a phenotype-genotype association study. *Lancet Infect Dis*. 2017;17:174–83. [http://dx.doi.org/10.1016/S1473-3099\(16\)30415-7](http://dx.doi.org/10.1016/S1473-3099(16)30415-7)
- Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD et al. Genetic markers associated with dihydroartemisinin-piperazine failure in *Plasmodium falciparum* malaria in Cambodia: a genotype-phenotype association study. *Lancet Infect Dis*. 2017;17:164–73. [http://dx.doi.org/10.1016/S1473-3099\(16\)30409-1](http://dx.doi.org/10.1016/S1473-3099(16)30409-1)

12. Dhingra SK, Redhi D, Combrinck JM, Yeo T, Okombo J, Henrich PP, et al. A variant PfCRT isoform can contribute to *Plasmodium falciparum* resistance to the first-line partner drug piperazine. *MBio*. 2017;8:e00303–17. <http://dx.doi.org/10.1128/mBio.00303-17>
13. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA. Decreasing *pfmdr1* copy number in *Plasmodium falciparum* malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. *J Infect Dis*. 2006;194:528–35. <http://dx.doi.org/10.1086/507115>
14. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in *Plasmodium falciparum* and increased *pfmdr1* gene copy number. *Lancet*. 2004;364:438–47. [http://dx.doi.org/10.1016/S0140-6736\(04\)16767-6](http://dx.doi.org/10.1016/S0140-6736(04)16767-6)
15. Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, et al. *Pfmdr1* copy number and artemisinin derivatives combination therapy failure in falciparum malaria in Cambodia. *Malar J*. 2009;8:11. <http://dx.doi.org/10.1186/1475-2875-8-11>
16. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, et al. The *pfmdr1* gene is associated with a multidrug-resistant phenotype in *Plasmodium falciparum* from the western border of Thailand. *Antimicrob Agents Chemother*. 1999;43:2943–9.
17. Wilson CM, Volkman SK, Thaitong S, Martin RK, Kyle DE, Milhous WK, et al. Amplification of *pfmdr1* associated with mefloquine and halofantrine resistance in *Plasmodium falciparum* from Thailand. *Mol Biochem Parasitol*. 1993;57:151–60. [http://dx.doi.org/10.1016/0166-6851\(93\)90252-S](http://dx.doi.org/10.1016/0166-6851(93)90252-S)
18. Gil JP, Krishna S. *pfmdr1* (*Plasmodium falciparum* multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies. *Expert Rev Anti Infect Ther*. 2017;15:527–43. <http://dx.doi.org/10.1080/14787210.2017.1313703>
19. Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, Kironde F, et al. Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania. *Malar J*. 2012;11:58. <http://dx.doi.org/10.1186/1475-2875-11-58>
20. Dokomajilar C, Nsobia SL, Greenhouse B, Rosenthal PJ, Dorsey G. Selection of *Plasmodium falciparum pfmdr1* alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. *Antimicrob Agents Chemother*. 2006;50:1893–5. <http://dx.doi.org/10.1128/AAC.50.5.1893-1895.2006>
21. Duraisingh MT, Cowman AF. Contribution of the *pfmdr1* gene to antimalarial drug-resistance. *Acta Trop*. 2005;94:181–90. <http://dx.doi.org/10.1016/j.actatropica.2005.04.008>
22. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. *Mol Cell*. 2000;6:861–71. [http://dx.doi.org/10.1016/S1097-2765\(05\)00077-8](http://dx.doi.org/10.1016/S1097-2765(05)00077-8)
23. Folarin OA, Bustamante C, Gbotsho GO, Sowunmi A, Zalis MG, Oduola AM, et al. In vitro amodiaquine resistance and its association with mutations in *pfcr1* and *pfmdr1* genes of *Plasmodium falciparum* isolates from Nigeria. *Acta Trop*. 2011;120:224–30. <http://dx.doi.org/10.1016/j.actatropica.2011.08.013>
24. Sá JM, Twu O, Hayton K, Reyes S, Fay MP, Ringwald P, et al. Geographic patterns of *Plasmodium falciparum* drug resistance distinguished by differential responses to amodiaquine and chloroquine. *Proc Natl Acad Sci U S A*. 2009;106:18883–9. <http://dx.doi.org/10.1073/pnas.0911317106>
25. Sisowath C, Petersen I, Veiga MI, Mårtensson A, Premji Z, Björkman A, et al. In vivo selection of *Plasmodium falciparum* parasites carrying the chloroquine-susceptible *pfcr1* K76 allele after treatment with artemether-lumefantrine in Africa. *J Infect Dis*. 2009;199:750–7. <http://dx.doi.org/10.1086/596738>
26. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, et al. Genetic architecture of artemisinin-resistant *Plasmodium falciparum*. *Nat Genet*. 2015;47:226–34. <http://dx.doi.org/10.1038/ng.3189>
27. Kublin JG, Dzinjalimala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of *Plasmodium falciparum* malaria. *J Infect Dis*. 2002;185:380–8. <http://dx.doi.org/10.1086/338566>
28. World Health Organization. Policy recommendation on intermittent preventive treatment during infancy with sulfadoxine-pyrimethamine (SP-IPTi) for *Plasmodium falciparum* malaria control in Africa. Geneva: The Organization. p. 1–3.
29. Petersen I, Eastman R, Lanzer M. Drug-resistant malaria: molecular mechanisms and implications for public health. *FEBS Lett*. 2011;585:1551–62. <http://dx.doi.org/10.1016/j.febslet.2011.04.042>
30. Hastings IM, Watkins WM. Intensity of malaria transmission and the evolution of drug resistance. *Acta Trop*. 2005;94:218–29. <http://dx.doi.org/10.1016/j.actatropica.2005.04.003>
31. Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. *Am J Hum Genet*. 2005;77:171–92. <http://dx.doi.org/10.1086/432519>
32. Ataide R, Ashley EA, Powell R, Chan JA, Malloy MJ, O’Flaherty K, et al. Host immunity to *Plasmodium falciparum* and the assessment of emerging artemisinin resistance in a multinational cohort. *Proc Natl Acad Sci U S A*. 2017;114:3515–20. <http://dx.doi.org/10.1073/pnas.1615875114>
33. Enosse S, Magnussen P, Abacassamo F, Gómez-Olivé X, Rønn AM, Thompson R, et al. Rapid increase of *Plasmodium falciparum dhfr/dhps* resistant haplotypes, after the adoption of sulfadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. *Malar J*. 2008;7:115. <http://dx.doi.org/10.1186/1475-2875-7-115>
34. Raman J, Mauff K, Muianga P, Mussa A, Maharaj R, Barnes KI. Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. *PLoS One*. 2011;6:e25992. <http://dx.doi.org/10.1371/journal.pone.0025992>
35. Galatas B, Nhamussua L, Candrinho B, Mabote L, Cisteró P, Gupta H, et al. In-vivo efficacy of chloroquine to clear asymptomatic infections in Mozambican adults: a randomized, placebo-controlled trial with implications for elimination strategies. *Sci Rep*. 2017;7:1356. <http://dx.doi.org/10.1038/s41598-017-01365-4>
36. Mayor A, Serra-Casas E, Bardají A, Sanz S, Puyol L, Cisteró P, et al. Sub-microscopic infections and long-term recrudescence of *Plasmodium falciparum* in Mozambican pregnant women. *Malar J*. 2009;8:9. <http://dx.doi.org/10.1186/1475-2875-8-9>
37. Taylor SM, Mayor A, Mombo-Ngoma G, Kenguele HM, Ouédraogo S, Ndam NT, et al. A quality control program within a clinical trial consortium for PCR protocols to detect *Plasmodium* species. *J Clin Microbiol*. 2014;52:2144–9. <http://dx.doi.org/10.1128/JCM.00565-14>
38. Ménard D, Khim N, Beghain J, Adegnikaa AA, Shafiu-alam M, Amodu O, et al.; KARMA Consortium. A worldwide map of *Plasmodium falciparum* K13-propeller polymorphisms. *N Engl J Med*. 2016;374:2453–64. <http://dx.doi.org/10.1056/NEJMoa1513137>
39. Salvador C, Rafael B, Matsinhe F, Candrinho B, Muthemba R, De Carvalho E, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria at sentinel sites in Mozambique. 2015. *Acta Trop*. 2017;171:146–50. <http://dx.doi.org/10.1016/j.actatropica.2017.03.032>



40. Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-propeller polymorphisms in *Plasmodium falciparum* parasites from sub-Saharan Africa. *J Infect Dis*. 2015;211:1352–5.
41. Andriantsoanirina V, Ratsimbaoa A, Bouchier C, Jahevitra M, Rabearimanana S, Radrianjafy R, et al. *Plasmodium falciparum* drug resistance in Madagascar: facing the spread of unusual *pfdhfr* and *pfmdr-1* haplotypes and the decrease of dihydroartemisinin susceptibility. *Antimicrob Agents Chemother*. 2009;53:4588–97. <http://dx.doi.org/10.1128/AAC.00610-09>
42. Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of *Plasmodium falciparum* malaria multidrug resistance to artemisinin and piperazine in western Cambodia: dihydroartemisinin-piperazine open-label multicenter clinical assessment. *Antimicrob Agents Chemother*. 2015;59:4719–26. <http://dx.doi.org/10.1128/AAC.00835-15>
43. Phuc BQ, Rasmussen C, Duong TT, Dong LT, Loi MA, Ménard D, et al. Treatment failure of dihydroartemisinin/piperazine for *Plasmodium falciparum* malaria, Vietnam. *Emerg Infect Dis*. 2017;23:715–7. <http://dx.doi.org/10.3201/eid2304.161872>
44. Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. *Trop Med Int Health*. 2006;11:1360–6. <http://dx.doi.org/10.1111/j.1365-3156.2006.01690.x>
45. Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, et al. Efficacy of dihydroartemisinin-piperazine for treatment of uncomplicated *Plasmodium falciparum* and *Plasmodium vivax* in Cambodia, 2008 to 2010. *Antimicrob Agents Chemother*. 2013;57:818–26. <http://dx.doi.org/10.1128/AAC.00686-12>
46. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin-piperazine resistance in *Plasmodium falciparum* malaria in Cambodia: a multisite prospective cohort study. *Lancet Infect Dis*. 2016;16:357–65. [http://dx.doi.org/10.1016/S1473-3099\(15\)00487-9](http://dx.doi.org/10.1016/S1473-3099(15)00487-9)
47. Chaorattanakawee S, Lon C, Jongsakul K, Gawee J, Sok S, Sundrakes S, et al. Ex vivo piperazine resistance developed rapidly in *Plasmodium falciparum* isolates in northern Cambodia compared to Thailand. *Malar J*. 2016;15:519. <http://dx.doi.org/10.1186/s12936-016-1569-y>
48. Escobar C, Pateira S, Lobo E, Lobo L, Teodosio R, Dias F, et al. Polymorphisms in *Plasmodium falciparum* K13-propeller in Angola and Mozambique after the introduction of the ACTs. *PLoS One*. 2015;10:e0119215. <http://dx.doi.org/10.1371/journal.pone.0119215>
49. World Health Organization. Status report on artemisinin and ACT resistance. 2015 [cited 2017 Mar 20]. <http://www.who.int/malaria/publications/atoz/status-rep-artemisinin-resistance-sept2015.pdf>
50. Isozumi R, Uemura H, Kimata I, Ichinose Y, Logedi J, Omar AH, et al. Novel mutations in K13 propeller gene of artemisinin-resistant *Plasmodium falciparum*. *Emerg Infect Dis*. 2015;21:490–2. <http://dx.doi.org/10.3201/eid2103.140898>

Address for correspondence: Alfredo Mayor, ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic, Universitat de Barcelona, Carrer Rosselló 153 (CEK Bldg), E-08036 Barcelona, Spain; email: [alfredo.mayor@isglobal.org](mailto:alfredo.mayor@isglobal.org)

## Now on Exhibit David J. Sencer CDC Museum

# EBOLA

OPEN THROUGH MAY 25, 2018

**People + Public Health + Political Will**

**EBOLA: People + Public Health + Political Will** is an investigation of the historic 2014–16 Ebola Fever Virus epidemic in West Africa, the United States, and around the world. As the crisis unfolded in Guinea, Liberia, and Sierra Leone in 2014, it evolved into both a health and humanitarian crisis. When it became clear that Ebola could potentially spread exponentially, threatening global health security, there was a coordinated, massive response.

#### Hours

Monday: 9 a.m.–5 p.m.  
 Tuesday: 9 a.m.–5 p.m.  
 Wednesday: 9 a.m.–5 p.m.  
 Thursday: 9 a.m.–7 p.m.  
 Friday: 9 a.m.–5 p.m.  
 Closed weekends and federal holidays

#### Location

1600 Clifton Road NE  
 Atlanta, GA 30329  
 Phone 404-639-0830  
 Admission and parking free  
 Government-issued photo ID required  
 for adults over the age of 18

**Free admission**

# Drug-Resistant Polymorphisms and Copy Numbers in *Plasmodium falciparum*, Mozambique, 2015

## Technical Appendix

### Sanger Sequencing

#### *pfmdr1* polymorphisms

*pfmdr1* gene was divided into two separate fragments (*pfmdr1\_f1* and *pfmdr1\_f2*). The *pfmdr1\_f1* and *pfmdr1\_f2* fragments were amplified separately in 25µl reactions including 5µl of template DNA, 0.5µM of each forward and reverse specific primer set for *pfmdr1\_f1* and *pfmdr1\_f2* fragments (Technical Appendix Table) and 1xHOT FirePol Master Mix (Solis BioDyne; Riia, Tartu, Estonia), reaction volume was raised by PCR-grade water. In a thermocycler, both the fragment amplification followed the same PCR conditions, the template DNA was denatured at 95°C for 15min, followed by 35 cycles of amplification (95°C for 1min, 60°C for 1min, and 72°C for 1min 30s) and a final extension at 72°C for 10min. PCR products were run on 2% agarose (Invitrogen, Carlsbad, CA, USA) gels in 1× TBE buffer (Invitrogen, Carlsbad, CA, USA) to determine the presence and size of the amplified DNA and PCR products were visualized using a UV trans-illuminator. The expected size of PCR products for *pfmdr1\_f1* and *pfmdr1\_f2* fragments was 610bp and 1295bp respectively. Whenever enough amplified products were not obtained, re-PCR were performed using the same primer sets and PCR conditions mentioned above for both *pfmdr1\_f1* and *pfmdr1\_f2* fragments, 5µl of PCR products were used as DNA templates for re-PCRs. To sequence the f1 and f2 fragments of *pfmdr1* gene, two new pairs of sequencing primers were used (Technical Appendix Table). The sequencing primer pair, specific for *pfmdr1\_f1* fragment, covers 45 – 209 aa and *pfmdr1\_f2* specific sequencing primer pair covered 984 – 1277 aa of PfMDR1 protein. The specificity of all primer sets was tested against human genomic DNA and no DNA template control.

### ***pfdhps* polymorphisms**

For *pfdhps* gene amplification, a single PCR based assay was designed. In brief, amplification was performed in 25µl reaction including 5µl of template DNA, 0.5µM of each forward and reverse specific primer set for *pfdhps* (Technical Appendix Table) and 1x HOT FirePol Master Mix, reaction volume was raised by PCR-grade water. The template DNA was denatured at 95°C for 15min in a thermocycler, followed by 32 cycles of amplification (95°C for 1min, 54°C for 1min, and 72°C for 1min) and a final extension at 72°C for 10 min. The expected size of the PCR product was 875bp was visualized as mentioned above covering 357- 647 aa of PfDHPS protein. PCR products were sequenced using a forward primer of PCR and new reverse sequencing primer (Technical Appendix Table) covering 357 – 477 aa of PfDHPS protein. Positive and negative (water instead of template DNA) controls were added in every PCRs and plates. The specificity of all primer sets was tested against human genomic DNA and no DNA template control.

For bi-directional sequencing, ≈1200ng of PCR products (quantified using EPOCH Biotech system) were sent to Genewiz (Takeley, United Kingdom), following safety instructions for the accurate shipment of PCR amplicons. The variations in the test sequences of *K13*, *pfert*, *pfmdr1* and *pfdhps* were identified by sequence alignment against PF3D7\_1343700, PF3D7\_0709000, PF3D7\_0523000 and PF3D7\_0810800 reference sequence of 3D7 respectively, retrieved from PlasmoDB.

### ***pfdhps* - Restriction fragment length polymorphism**

To detect the K540E polymorphism in *pfdhps*, the restriction fragment length polymorphism (RFLP) was performed. The PCR products of 875bp (described above) of *Pfdhps* gene were digested with FokI enzyme (New England Biolabs, Ipswich, MA, USA) as per manufacture instruction's which generated 538bp, 315bp and 22bp fragments whenever mutant allele was present, and two fragments of 853bp and 22bp were seen for wild type allele.

### ***pfmdr1* and *pfpm2* gene copy number - qPCR**

The quantitative PCR (qRT-PCR) was used to assess variations in the copy number (CN) of *pfpm2* and *pfmdr1* genes as described elsewhere (1) with minor changes. In brief, 96-well plates were prepared containing separate 20µl reaction mixtures for *pfpm2*, *pfmdr1* and *pfβ-tubulin* genes. *Pfβ-tubulin* gene was used as an endogenous control. Each reaction mixture had

2X Power SYBR<sup>®</sup> Green PCR Master Mix (Thermo Fisher Scientific, Warrington, WA, UK), 0.25  $\mu$ M of each forward and reverse primers and 5 $\mu$ l of template DNA, reaction volume was makeup by PCR-grade water. Amplifications were performed with a holding for 3mins at 50°C, initial denaturation for 10mins at 95°C, followed by 40 cycles of 95°C for 15s and 58°C for 45s, extra dissociation stage was added to ensure the specificity of primer pairs. The 20 $\mu$ l reaction mixtures in a 96-well plate were amplified in a 7500 HT Real-Time System (Applied Biosystem, Foster City, USA). For each run, the *pfpm2* and *pfmdr1* copy numbers of each sample were measured in triplicate. The PCR efficiencies of the *pfpm2*, *pfmdr1* and *pf $\beta$ -tubulin* genes were measured using ten-fold dilutions of 3D7 DNA. The specificity of three primer pairs against human genomic DNA was also determined. Along with no template control, we also included one positive control with the known 3-4 copies of *pfpm2* gene provided by Dr. Didier Ménard (Pasteur Institute, Cambodia) and another positive control for *pfmdr1* gene, genomic DNA of DD2 parasite line with known 3-4 copies of *pfmdr1*. All samples with  $C_t > 33$  for *pfpm2*, *pfmdr1* and *pf $\beta$ -tubulin* were not considered for the CN analysis. The *pfmdr1* and *pfpm2* genes CNs were estimated as described previously (1). All samples with estimated CN values above 1.5 were confirmed two more times.


## Reference

1. Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J et al. A surrogate marker of piperazine-resistant *Plasmodium falciparum* malaria: a phenotype-genotype association study. Lancet Infect Dis. 2017;17:174–83. [http://dx.doi.org/10.1016/S1473-3099\(16\)30415-7](http://dx.doi.org/10.1016/S1473-3099(16)30415-7)

**Technical Appendix Table.** The sequence of the oligonucleotides used for PCR and sequencing, PCR annealing temperature (T<sub>m</sub>), several cycles, the size of amplicons and covered amino acids

Gene	Conventional PCR			Sequencing		
	PCR primers	Annealing Temp (°C)	Cycles	PCR size (bp)	Sequencing primers	Covered amino acids
<i>K13</i>	OuterF:cggagtgaccaaactctggga	58	30	2097	F:gccaagctgccattcattg	427–709
	OuterR:gggaatctggtgtaacagc					
	NestedF:gccaagctgccattcattg	60	40	849	R:gccttggtgaaagaagcaga	
<i>pfcr1</i>	NestedR:gccttggtgaaagaagcaga	52	25	569	F:tttagtgagggttctgtctt	35–120
	OuterF:tttagtgagggttctgtctt					
	OuterR:atacttaattgaagaacaaatgattgga	50	35	319	R:ttgtagtggaatagattctct	
<i>pfmdr1_F1</i>	NestedF:tttagtgagggttctgtctt	60	35	610	F:ccgtttaaatgtttacctgcac	45–209
	NestedR:ttgtagtggaatagattctct					
<i>pfmdr1_F2</i>	F:agagaaaaaagatggtaacctcag	60	35	1295	F:ttttaatacaggaagcatttt	984–1277
	R:accacaacataaattaacgg					
<i>pfdhps</i>	F:accccaggtgtttatctgc	54	32	875	F:tgtagtaggatgaaagaacaa	357–477
	R:tgccacctgataagctttacc					
	F:tgtagtaggatgaaagaacaa				R:attggttgcacacatt	
	R:tccaattgtgattgtcca					





**Technical Appendix Figure.** Assessment of the detection limit by Sanger sequencing in artificially mixed DNA samples, containing various proportions of *pfcr1* (K76T) and *pfmdr1* (Y184F and S1034C) alleles. Panel A: K76T polymorphism of *pfcr1* gene; Panel B and C is for Y184F and S1034C polymorphisms of *pfmdr1* gene, respectively.

### Additional Text References

51. Torrentino-Madamet M, Fall B, Benoit N, Camara C, Amalvict R, Fall M, et al. Limited polymorphisms in k13 gene in *Plasmodium falciparum* isolates from Dakar, Senegal in 2012-2013. *Malar J.* 2014;13:472. [PubMed http://dx.doi.org/10.1186/1475-2875-13-472](http://dx.doi.org/10.1186/1475-2875-13-472)
52. Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H et al. Emergence of indigenous artemisinin-resistant *Plasmodium falciparum* in Africa. *N Engl J Med.* 2017; 376:991–53. <http://dx.doi.org/10.1056/NEJMc1612765>

53. Thomsen TT, Madsen LB, Hansson HH, Tomás EV, Charlwood D, Bygbjerg IC, et al. Rapid selection of *Plasmodium falciparum* chloroquine resistance transporter gene and multidrug resistance gene-1 haplotypes associated with past chloroquine and present artemether-lumefantrine use in Inhambane District, southern Mozambique. *Am J Trop Med Hyg.* 2013;88:536–41. [PubMed http://dx.doi.org/10.4269/ajtmh.12-0525](http://dx.doi.org/10.4269/ajtmh.12-0525)
54. Mekonnen SK, Aseffa A, Berhe N, Teklehaymanot T, Clouse RM, Gebru T, et al. Return of chloroquine-sensitive *Plasmodium falciparum* parasites and emergence of chloroquine-resistant *Plasmodium vivax* in Ethiopia. *Malar J.* 2014;13:244. [PubMed http://dx.doi.org/10.1186/1475-2875-13-244](http://dx.doi.org/10.1186/1475-2875-13-244)
55. Frosch AE, Laufer MK, Mathanga DP, Takala-Harrison S, Skarbinski J, Claassen CW, et al. Return of widespread chloroquine-sensitive *Plasmodium falciparum* to Malawi. *J Infect Dis.* 2014;210:1110–4. [PubMed http://dx.doi.org/10.1093/infdis/jiu216](http://dx.doi.org/10.1093/infdis/jiu216)
56. Ndam NT, Basco LK, Ngane VF, Ayouba A, Ngolle EM, Deloron P, et al. Reemergence of chloroquine-sensitive pfprt K76 *Plasmodium falciparum* genotype in southeastern Cameroon. *Malar J.* 2017;16:130. [PubMed http://dx.doi.org/10.1186/s12936-017-1783-2](http://dx.doi.org/10.1186/s12936-017-1783-2)
57. Laufer MK, Plowe CV. Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. *Drug Resist Updat.* 2004;7:279–88. [PubMed http://dx.doi.org/10.1016/j.drug.2004.08.003](http://dx.doi.org/10.1016/j.drug.2004.08.003)
58. Lobo E, de Sousa B, Rosa S, Figueiredo P, Lobo L, Pateira S, et al. Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy. *Malar J.* 2014;13:300. [PubMed http://dx.doi.org/10.1186/1475-2875-13-300](http://dx.doi.org/10.1186/1475-2875-13-300)
59. Desai M, Gutman J, Taylor SM, Wiegand RE, Khairallah C, Kayentao K, et al. Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight. *Clin Infect Dis.* 2016;62:323–33. [PubMed http://dx.doi.org/10.1093/cid/civ881](http://dx.doi.org/10.1093/cid/civ881)
60. Gutman J, Mwandama D, Wiegand RE, Ali D, Mathanga DP, Skarbinski J. Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi. *J Infect Dis.* 2013;208:907–16. [PubMed http://dx.doi.org/10.1093/infdis/jit276](http://dx.doi.org/10.1093/infdis/jit276)

61. Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. *JAMA*. 2013;309:594–604. [PubMed http://dx.doi.org/10.1001/jama.2012.216231](http://dx.doi.org/10.1001/jama.2012.216231)
62. World Health Organization. Intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-sulfadoxine-pyrimethamine). Updated WHO Policy Recommendation. 2012. Geneva: The Organization. p. 1–3.
63. Laufer MK, van Oosterhout JJ, Thesing PC, Thumba F, Zijlstra EE, Graham SM, et al. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. *J Infect Dis*. 2006;193:872–8. [PubMed http://dx.doi.org/10.1086/500245](http://dx.doi.org/10.1086/500245)
64. Artimovich E, Schneider K, Taylor TE, Kublin JG, Dzinjalama FK, Escalante AA, et al. Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi. *J Infect Dis*. 2015;212:694–701. [PubMed http://dx.doi.org/10.1093/infdis/jiv078](http://dx.doi.org/10.1093/infdis/jiv078)